With the EMA relocating it’s headquarters out of London as a result of the Brexit vote, the organisation is also planning a restructure, losing one of the divisions that deals with human medicines and renewing its focus on collaborations with member state competent authorities.
Main changes include:
- Cutting one division dealing with human medicines (ie. Going from four to three, with one division responsible for support to medicines developers, one for the evaluation of medicines bringing scientific and procedure management under one umbrella, and one for the oversight of medicines, including pharmacovigilance and inspections)
- Creating a new function dedicated to strengthening the collaboration between EMA and national competent authorities by overseeing the implementation of a joint network strategy to 2020, promoting innovation in regulatory science across the EU and addressing the increasing complexity of its committees’ coordination of activities
- “Streamlining the division dealing with administration and corporate management through separate entities for strategic planning, budgeting and monitoring, finance and procurement, and support to staff and delegates”
The EMA also added that interactions between stakeholders and the agency will not be affected by these changes.